Clinical Trial Update: Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) [Phase 3]

View source ↗

Summary

Phase 3 trial in symptomatic benign prostatic hypertrophy evaluating cetrorelix pamoate regimens; study terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hypertrophy

Drugs mentioned

• Cetrorelix Pamoate (cetrorelix pamoate)

Snippet

Sponsor: AEterna Zentaris | Conditions: Benign Prostatic Hypertrophy | Phase 3 | Status: TERMINATED | Results posted: 2011-01-19